Assessment of tumoricidal efficacy and response to treatment with 18F-FDG PET/CT after intraarterial infusion with the antiglycolytic agent 3-bromopyruvate in the VX2 model of liver tumor

18Citations
Citations of this article
25Readers
Mendeley users who have this article in their library.

Abstract

The purpose of this study was to determine the effects of 3-bromopyruvate (3-BrPA) on tumor glucose metabolism as imaged with 18F-FDG PET/CT at multiple time points after treatment and compare them with those after intraarterial control injections of saline. Methods: Twenty-three New Zealand White rabbits implanted intrahepatically with VX2 tumors were assigned to 1 of 2 groups: 14 rabbits were assigned to the treatment group (TG) and 9 to the saline control group (SG). All animals were infused with 25 mL of either 1.75 mM 3-BrPA or saline over 1 h via a 2-French catheter, which was secured in the hepatic artery. For PET/CT, the animals were injected with 37 MBq of 18F-FDG at 1 d before treatment and 2 h, 24 h, and 1 wk after treatment. Tumor size, tumor and liver maximal standardized uptake value (SUVmax), and tumor-to-background ratios were calculated for all studies. Seven TG and 5 SG animals were sacrificed at 1 wk after treatment for histopathologic analysis. Results: Intense 18F-FDG uptake was seen in untreated tumors. A significant reduction in tumor SUVmax was noted in TG animals, when compared with SG animals, at 1 wk after treatment (P = 0.006). The tumor-to-liver background ratio in the TG animals, compared with the SG animals, was significantly reduced as early as 24 h after treatment (P = 0.01) and remained reduced at 1 wk (P = 0.003). Tumor SUVmax increased from the baseline levels at 7 d in controls (P = 0.05). The histopathologic analysis of explanted livers revealed increased tumor necrosis in all TG samples. There was a significant inverse correlation (r2 = 0.538, P = 0.005) between the percentage of tumor necrosis on histopathology and tumor SUVmax on 18F-FDG PET at 7 d after treatment with 3-BrPA. Conclusion: Intraarterial injection of 3-BrPA resulted in markedly decreased 18F-FDG uptake as imaged by PET/CT and increased tumor necrosis on histopathology at 1 wk after treatment in the VX2 rabbit liver tumor. PET/CT appears to be a useful means to follow antiglycolytic therapy with 3-BrPA. Copyright © 2011 by the Society of Nuclear Medicine, Inc.

References Powered by Scopus

On the origin of cancer cells

11023Citations
N/AReaders
Get full text

From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors

3100Citations
N/AReaders
Get full text

Tumor Cell Metabolism: Cancer's Achilles' Heel

1881Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Targeting glucose metabolism to suppress cancer progression: prospective of anti-glycolytic cancer therapy

377Citations
N/AReaders
Get full text

3-bromopyruvate: Targets and outcomes

127Citations
N/AReaders
Get full text

Interventional oncologic approaches to liver metastases

93Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Liapi, E., Geschwind, J. F. H., Vali, M., Khwaja, A. A., Prieto-Ventura, V., Buijs, M., … Wahl, R. L. (2011). Assessment of tumoricidal efficacy and response to treatment with 18F-FDG PET/CT after intraarterial infusion with the antiglycolytic agent 3-bromopyruvate in the VX2 model of liver tumor. Journal of Nuclear Medicine, 52(2), 225–230. https://doi.org/10.2967/jnumed.110.083162

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 12

67%

Researcher 4

22%

Professor / Associate Prof. 2

11%

Readers' Discipline

Tooltip

Medicine and Dentistry 15

68%

Agricultural and Biological Sciences 6

27%

Biochemistry, Genetics and Molecular Bi... 1

5%

Save time finding and organizing research with Mendeley

Sign up for free